Compare Incyte Corporation (INCY) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Old Dominion Freight Line Inc — how do they compare? Incyte Corporation trades at $121.35 (market cap $24.54B), while Old Dominion Freight Line Inc trades at $212.6 (market cap $43.43B). The key difference: Old Dominion Freight Line Inc is the larger of the two by market cap, and Old Dominion Freight Line Inc pays a 0.55% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | ODFL | |
|---|---|---|
Market Cap | $24.54B | $43.43B |
Sector | Health | Industrials |
52-Week High | $129.93 | $248.73 |
52-Week Low | $81.61 | $126.29 |
Enterprise Value | $20.04B | $43.17B |
Dividend Yield | — | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
ODFL trades at $212.55, down 1.76% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 19.44% net margins and 24.82% ROE, though valuation metrics remain elevated with a P/E of 40.28. Recent Q2 2026 earnings of $1.68 per share exceeded expectations, driven by yield improvements and cost discipline amid ongoing freight market pressures.
The stock faces headwinds from premium valuation and mixed analyst sentiment (33% buy, 56% hold), but strong fundamentals and consistent earnings outperformance provide support. Key risks include freight volume recovery uncertainty and execution pressure given high expectations. The consensus price target of $239.85 suggests 13% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
